GlassScriptPhysician profile
Kevin M Rufner
NPI 1427195718
$7,823.31
in general payments reported to CMS, 2019-2025
38 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $582 · 2021: $759 · 2022: $1,312 · 2023: $1,604 · 2024: $1,416 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,870 · Education: $88.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,870.47 |
| Education | $88.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.03 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $948.91 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $717.64 | 2019-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $600.97 | 2019-2025 | |
| Celgene Corporation | $476.35 | 2021-2024 | Zeposia |
| Pfizer INC. | $337.86 | 2019-2024 | |
| Genzyme Corporation | $289.94 | 2022-2025 | |
| Braintree Laboratories, INC. | $261.67 | 2019-2025 | Suflave |
| Celltrion USA INC. | $232.60 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Lilly USA, LLC | $205.85 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $198.18 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $151.95 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Organon LLC | $96.36 | 2022-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $95.80 | 2023 | Idacio |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,517.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Rufner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.